In this episode, Dr. Dave Rabin is joined by Dr. John J. Miller, a renowned clinical psychopharmacologist, to discuss the significance of the upcoming FDA decision on MDMA therapy for PTSD.

John J. Miller, M.D. is Medical Director at Brain Health in Exeter, New Hampshire and has served as the Editor-in-Chief for Psychiatric Times since February 2019. He has worked for 38 years as a clinical psychopharmacologist, most recently 17 years as a Staff Psychiatrist at Seacoast Mental Health Center in Exeter, NH. Dr. Miller completed his B.S. in Biochemistry at the University of MA/Amherst. And medical school  and residency in Adult Psychiatry at the University of MA Medical School/Worcester. He is a Diplomate of the American Board of Psychiatry and Neurology. Since 1998 he has presented more than 3,000 lectures throughout the US on a wide range of psychiatric topics including PTSD. You can find Dr. Miller in his monthly editorials for Psychiatric Times that he has been authoring since March 2019.

Discover the history of PTSD treatment, the current limitations of existing medications, and the promising results of MDMA-assisted therapy trials. Learn about the bipartisan support from lawmakers and the urgent need for FDA approval to provide relief to millions suffering from PTSD.

Don't miss this insightful conversation on the potential paradigm shift in mental health treatment. Stay informed and advocate for change by tuning in to The Psychedelic Report.

Brain Health in Exeter, New Hampshire (http://www.brain-health.co)
Psychiatric Times (http://www.psychiatrictimes.com)
https://x.com/PsychTimes?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

https://www.linkedin.com/in/jjmillermd/

https://www.linkedin.com/company/psychiatric-times/

www.apolloneuro.com

FDA petition for MDMA-assisted therapy
https://healingmaps.com/sign-the-petition-to-approve-mdma-therapy/

Learn more about your ad choices. Visit megaphone.fm/adchoices